Table 3.

Prevalence of and cumulative incidences of SC and SR to active CC in 2,211 individuals eligible for follow-up consenting to the serological component of a study conducted in 60 villages of Burkina Faso, who had samples both at the baseline and pre-randomization 18-month follow-up visits

Parameter	Province	Total	n	% (95% CI)
Prevalence (baseline)	Boulkiemde	1,128	48	4.3 (3.2; 5.6)
	Nayala	434	12	2.8 (1.6; 4.8)
	Sanguie	349	7	1.1 (0.01; 2.2)
	Total	2,211	67	3.0 (2.4; 3.8)
Prevalence (18 month follow-up)	Boulkiemde	1,128	76	6.7 (5.4; 8.4)
	Nayala	434	20	4.6 (3.0; 7.0)
	Sanguie	349	18	2.8 (1.8; 4.4)
	Total	2,211	114	5.2 (4.3; 6.2)
SC	Boulkiemde	1,080	43	4.0 (2.9; 5.3)
	Nayala	422	14	3.3 (1.8; 5.5)
	Sanguie	642	14	2.2 (1.2; 3.6)
	Total	2,144	71	3.3 (2.6; 4.2)
SR	Boulkiemde	48	15	31.3 (18.7; 46.3)
	Nayala	12	6	50.0 (21.1; 78.9)
	Sanguie	7	3	42.9 (9.9; 81.6)
	Total	67	24	35.8 (24.5; 48.5)

SC = seroconversion; SR = seroreversion; 95% CI = 95% binomial exact confidence interval.